Autopsy report · NCT00277303
Study of XL999 in Patients With Metastatic Colorectal Cancer
Cause of deathSafety
“Study was terminated due to cardiac toxicities in the subjects”
Life of this trial
- Ran for about 1 year 2 months before it stopped.
- 17 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Symphony Evolution, Inc.
- Sponsor type
- Industry
- Conditions
- Colorectal Cancer
- Interventions
- XL999
- Participants
- 17
- Sites
- 8
- Countries
- United States
Trials that died the same way
- Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer
“Study terminated due to toxicity” - Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients
“The study has been prematurely terminated due to the onset of 2 dose limiting toxicities in 2 patients.” - A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors
“Study was prematurely discontinued due to unacceptable toxicity.” - A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)
“This study was terminated due to limited efficacy and not due to safety reasons” - A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia
“The study was terminated due to lack of efficacy at any of the tested doses on 18th November 2022. The decision to terminate the study is not related to a safety concern.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.